Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting
May 21 2014 - 7:05AM
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company
developing and commercializing innovative, targeted oncology
treatments that address major unmet medical needs to advance cancer
care, today announced that data from the Company's Phase 1 study
with GALE-301, or Folate Binding Protein, will be presented at the
upcoming American Society of Clinical Oncology (ASCO) 50th Annual
Meeting.
Abstract #5559 is entitled, "Comparison of recurrent and
nonrecurrent ovarian and uterine cancer patients undergoing
adjuvant folate receptor vaccine therapy." The data will be
presented during the Gynecologic Cancer General Poster Session on
Saturday May 31, 2014 from 8:00 am to 11:45 am CDT in S Hall
A2.
About GALE-301 (Folate Binding Protein (FBP)
vaccine)
GALE-301 (Folate Binding Protein (FBP)) cancer immunotherapy
targets FBP, a well-validated therapeutic target, which is highly
over-expressed in breast, ovarian and endometrial cancers. FBP is
the source of immunogenic peptides that can stimulate cytotoxic T
lymphocytes (CTLs) to recognize and destroy presenting
FBP-expressing cancer cells. The FBP vaccine consists of the
FBP peptide(s) combined with the immune adjuvant, granulocyte
macrophage-colony stimulating factor (GM-CSF). Galena's
FBP vaccine is currently in a Phase 1/2 trial in two gynecological
cancers: ovarian and endometrial adenocarcinomas.
About Ovarian/Endometrial Cancers
Ovarian cancer occurs in more than 22,000 patients per year in
the U.S. and is the most lethal gynecologic cancer. Despite the
incidence of ovarian cancer being only approximately 20% of that of
breast cancer, the number of patients that die from ovarian cancer
is nearly 50% of that of breast cancer. Due to the lack of specific
symptoms, the majority of ovarian cancer patients are diagnosed at
later stages of the disease. These patients have their tumors
routinely surgically debulked to minimal residual disease, and then
are treated with platinum- and/or taxane-based chemotherapy. While
most patients respond to this treatment regimen and become
clinically free-of-disease, the majority of these patients will
relapse, and once the disease recurs, the treatment options and
successes drop dramatically.
Endometrial cancer is the most common gynecologic cancer and
occurs in more than 46,000 women with more than 8,000 deaths in the
U.S. annually. There are two basic types of endometrial cancer:
endometrioid and papillary serous. The latter has a much more
aggressive clinical course and the majority of these patients will
die of this form of the disease.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a Portland, Oregon-based
biopharmaceutical company developing and commercializing
innovative, targeted oncology treatments that address major unmet
medical needs to advance cancer care. For more information
visit www.galenabiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to,
statements about the progress of the commercialization of Abstral®
and development of Galena's product candidates, including patient
enrollment in our clinical trials, as well as statements about our
expectations, plans and prospects. These forward-looking statements
are subject to a number of risks, uncertainties and assumptions,
including those identified under "Risk Factors" in Galena's Annual
Report on Form 10-K for the year ended December 31, 2013 and
Quarterly Report on Form 10-Q for the quarter ended March 31, 2014
filed with the SEC. Actual results may differ materially from
those contemplated by these forward-looking statements. Galena does
not undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this press release.
CONTACT: Remy Bernarda
VP, Marketing & Communications
(503) 405-8258
rbernarda@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024